Dec. 18, 2024 — Until now, scientists have been unable to determine how metformin, a Type 2 diabetes medication that lowers blood sugar, works. A study provided direct evidence in mice that it ...

Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have been given an average rating of “Hold” by the seven analysts that are presently covering the company, Marketbeat.com reports. Seven analysts ...

StockNews.com began coverage on shares of Catalent (NYSE:CTLT – Free Report) in a research report sent to investors on Friday ...

S&P MidCap 400 constituent Lennox International Inc. (NYSE: LII) will replace Catalent Inc. (NYSE: CTLT) in the S&P 500, ...

Novo Holdings said that it completed it's $16.5 billion acquisition of Catalent Inc. (NYSE:CTLT). Shortly following the ...

Novo Nordisk plans to buy from the holding company three sites — Brussels; Anagni, Italy; and Bloomington — for $11.7 billion ...

Novo Holdings has completed its $16.5 billion takeover of Catalent, the contract drug manufacturer announced on Wednesday, ...

Novo Nordisk will soon acquire from Novo Holdings Catalent’s three fill-finish sites located in Italy, the U.S., and Belgium.

(RTTNews) - Wednesday, Novo Holdings A/S completed the acquisition of Catalent, Inc. (CTLT), a global contract development and manufacturing organization, in an all-cash transaction worth ...

Dec 18 (Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, on Wednesday sealed its $16.5 billion deal for Catalent (CTLT.N), opens new tab ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

In recent trading, shares of Catalent Inc (Symbol: CTLT) have crossed above the average analyst 12-month target price of $63.42, changing hands for $63.48/share. When a stock reaches the target an ...